ERBB2 and cancer: Among others, worth mentioning are four published in the New England of Medicine on therapy combinations with anti-HER2 or cetuximab in breast and head and neck cancers, respectively—combinations that were later approved by the FDA [9–12] and saved the lives of thousands of cancer patients.